Basic information Safety Supplier Related

MSOP

Basic information Safety Supplier Related

MSOP Basic information

Product Name:
MSOP
Synonyms:
  • MSOP
  • (RS)-ALPHA-METHYLSERINE-O-PHOSPHATE
  • (R,S)-a-Methylserine-O-phosphate
  • (RS)-α-Methylserine-O-phosphate
  • Serine, 2-methyl-O-phosphono-
  • 2-Methyl-O- phosphonoserine
  • MSOP, group III metabotropic glutamate receptor antagonist
CAS:
66515-29-5
MF:
C4H10NO6P
MW:
199.1
Product Categories:
  • Glutamate receptor
Mol File:
66515-29-5.mol
More
Less

MSOP Chemical Properties

Boiling point:
454.0±55.0 °C(Predicted)
Density 
1.681±0.06 g/cm3(Predicted)
storage temp. 
Store at RT
solubility 
H2O: soluble3mg/mL, clear (warmed)
form 
powder
pka
1.66±0.10(Predicted)
color 
white to beige
Water Solubility 
Soluble to 100 mM in water
More
Less

Safety Information

Hazard Codes 
T
Risk Statements 
25
Safety Statements 
45
RIDADR 
UN 2811 6.1 / PGIII
WGK Germany 
3
More
Less

MSOP Usage And Synthesis

Uses

MSOP is a selective antagonist of group III mGlu receptors.

Biological Activity

MSOP is a selective group III metabotropic glutamate receptor antagonist. Displays an apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR on primary afferent terminals in spinal cord compared to > 700 μM for the (1S,3S)-ACPD-sensitive presynaptic mGlu in the same system. Has no activity on postsynaptic mGlu receptors or on ionotropic glutamate receptors on neonatal rat motoneurons.

in vivo

It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F3,16=30.96, P<0.001; CFA model: F3,16=30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group[2].

storage

Store at RT

MSOPSupplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
EMMX Biotechnology LLC
Tel
888-539-0666
Email
info@emmx.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
BOC Sciences
Tel
Email
info@bocsci.com
MedBioPharmaceutical Technology Inc
Tel
021-69568360 18916172912
Email
order@med-bio.cn
More
Less

MSOP(66515-29-5)Related Product Information